Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — LHA Life Sciences & Medical Technology Virtual Conference (June 2011)
37 slides from Aethlon Medical's conference presentation, Jun 17, 2011
Slide 1: Aethlon Medical – LHA Virtual Conference
aethlon MEDICAL, IN LHA Life Sciences & Medical Technology Virtual Conference June 16, 2014 Jim Joyce Chairman, CEO OTCBBAEMD:
Slide 2: Forward Looking Statements
Forward Looking Statements ‘This presentation contains predation, estimates and other forward-dooking statements that involve risks and uncertainties, including whether and when our Aethion ADAPT™ System, Hemopurifer® and other product offerings are successfully developed and introduced, market acce
Slide 3: Our mission is to create innovative devices
Our mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions
Slide 4: Investment Highlights
Investment Highlights Adaptable Therapeutic Filtration Device Platform Our Products Address Unmet Medical Needs Our Products Address Large Markets Early Adopter Distribution Channel in Place 4 Paths To Early Revenue New Clinical Programs
Slide 5: The Aethlon ADAPT System
The Aethlon ADAPT™ System Adaptive Dialysis-like Affinity Platform Technology Converges proven plasma membrane technology with antibodies or other affinity drug agents Provides foundation for an expansive pipeline of selective therapeutic filtration (STF) devices Transforms drug agent mechanism from
Slide 6: The ADAPT System Pipeline
The Adapt™ System Pipeline Introduced to the drug industry on May 25", 2011 * The Aethlon Hemopurifier® * STF device to reduce incidence of sepsis + Proposed in DARPA Dialysie-ike Therapeutics contract responce * STF device to address trauma related organ failure + Tobe proposed in forthcoming U.S.
Slide 7: The Hemopurifier
The Hemopurifier® The first medical device to selectively remove infectious viruses and immunosuppressive particles from circulation
Slide 8: The Hemopurifier: A Broad-Spectrum Therapeutic Device
The Hemopuritier® A Broad-Spectrum Therapeutic Device Hepatitis C HIV Cancer Bioterror & Pandemic Threats actinlon/@)
Slide 9: Investment Highlight: Addresses Unmet Medical Needs
Investment Highlight The Hemopurifier® Addresses Unmet Medical Needs
Slide 10: Bioterror & Pandemic Threats
Bioterror & Pandemic Threats Unmet Medical Need Targeted by the Aethlon Hemopurifier® © Fulfills the HHS broad-spectrum treatment mandate * Solution for emerging or released pathogens not addressed by drugs or vaccines: * Solution for genetically modified or synthetically enaineered pathogens
Slide 11: Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) Unmet Medical Need Targeted by the Aethlon Hemopurifier® * Assolution to drug resistance © Removes all viral strains * Captures immunosuppressive gpi20 aethion/@)
Slide 12: Hepatitis C Virus (HCV)
Hepatitis C Virus (HCV) Unmet Medical Need Targeted by the Aethlon Hemopurifier® Addresses all genotypes Accelerates viral load depletion wlo drug toxicity and interaction risks Selective mechanism advances proven benefit of therapeutic filtration without removing essential blood components
Slide 13: Hepatitis C Virus (HCV)
Hepatitis C Virus (HCV) Unmet Medical Need Targeted by the Aethlon Hemopurifier® Addresses all genotypes Accelerates viral load depletion wlo drug toxicity and interaction risks Selective mechanism advances proven benefit of therapeutic filtration without removing essential blood components
Slide 14: Cancer
Cancer Unmet Medical Need Targeted by the Aethlon Hemopurifier® The first therapeutic strategy to address exosomes released by cancer Induce apoptosis, Disrupt T-cell signaling Inhibit anti-cancer cytokine production Angiogenesis Metastasis
Slide 15: Does The Hemopurifier Really Have Broad-Spectrum Capabilities?
Question? Does The Hemopurifier® Really Have Broad-Spectrum Capabilities?
Slide 16: In Vitro Confirmations Against Bioterror and Pandemic Threats
In Vitro Confirmations Against Bioterror and Pandemic Threats Virus Collaborator Ebola Dengue Lassa West Nile HSN1 Avian 1918-1 Spanish Flu 2009 H1N1 Swine Monkey Pox USAMRIID/CDC NIVWHO SFBR Battelle Battelle Battelle Battelle Battelle
Slide 17: HIV-AIDS Study
HIV-AIDS Study Infected dialysis patient 12 treatments / 30 days 4 hrs per treatment Performed in absence of drug therapy Average per treatment viral load reduction of 54% Improved CD4 t-cell ratios Start Finish
Slide 18: Human HCV Studies
Human HCV Studies Average per treatment viral load 64% Reduction reduction of 64% Infected dialysis patients 4 hour treatments Performed in absence of drug therapy Calculated from 36 treatments Finish
Slide 19: In vitro Cancer Exosome Validations
In vitro Cancer Exosome Validations © Ovarian ¢ Breast * Colorectal * Lymphoma Melanoma.
Slide 20: Investment Highlight: Large Market Disease Conditions
Investment Highlight The Hemopurifier® Addresses Large Market Disease Conditions
Slide 21: Size of Hemopurifier Markets
Size of Hemopurifier® Markets Not Inclusive of Biodefense & Pandemic Opportunities HIV HCV ® Cancer
Slide 22: $ Value of Hemopurifier Markets
$ Value of Hemopurifier® Markets Not Inclusive of Biodefense & Pandemic Opportunities
Slide 23: Investment Highlight: Early Adopter Distribution Channel
Investment Highlight Early Adopter Distribution Channel in Place
Slide 24: Hemopurifier therapy via global dialysis infrastructure
Hemopurifier® therapy can be delivered through the established global infrastructure of dialysis machines (90,000 in U.S. alone)
Slide 25: The Early Adopter Distribution Channel
The Early Adopter Distribution Channel 20,000 Nephrologists who will know how to administer Hemopurifier® therapy Over 15,000 dialysis centers available to become official Hemopurifier® therapy locations No additional infrastructure required 2 million dialysis patients already being treated by Nephr
Slide 26: The Future
The Future Home delivery of the Hemopurifier® and other devices: evolved from the Aethlon ADAPT™ system
Slide 27: Investment Highlight: Paths to Early Revenue
Investment Highlight 4 Paths to Early Revenue
Slide 28: Paths to Early Revenue
4 Paths to Early Revenue . Aethlon ADAPT™ system revenues Government Contract or Grant Income Research Diagnostics Hemopurifier® Commericialization
Slide 29: Paths to Early Revenue: ADAPT System Revenues
4 Paths to Early Revenue 1.) Aethlon ADAPT™ System Revenues Multi-channel revenue opportunity driven by future products created through drug industry collaborations Product development fees Fees from research, regulatory, and manufacturing support Downstream royalties
Slide 30: Paths to Early Revenue: Government Contract or Grant Income
4 Paths to Early Revenue 2.) Government Contract or Grant Income Pending - Response to DARPA-BAA-1 1-30 entitled, “Dialysis-Like Therapeutics” submitted April 1, 2011 Pending — Response to BARDA CBRN BAA-11-100-00009 submitted on May 31, 2011 Forthcoming submission — U.S. Army, Blood Purification fo
Slide 31: Paths to Early Revenue: Research Diagnostics
4 Paths to Early Revenue 3.) Research Diagnostics Licensing or initial sales of our ELLSA research diagnostic tools that identify and quantify exosomes
Slide 32: Paths to Early Revenue: Hemopurifier Commercialization
4 Paths to Early Revenue 4.) Hemopurifier® Commercialization A 30 patient study underway at the Medanta-Medicity Institute in Delhi, India Treatment target: HCV Primary study objective: To demonstrate Hemopurifier® therapy accelerates early viral load depletion when combined with HCV- SOC therapy Ac
Slide 33: Investment Highlight: Expansion of Clinical Programs
Investment Highlight Expansion of Clinical Programs
Slide 34: Expansion of Clinical Programs
Expansion of Clinical Programs ical program op} We plan to request permission from FDA to initiate U.S. clinical programs this summer IDE on file related to treatment of bioterror and pandemic threats We will also seek permission from FDA to expand label indication to include treatment of HCV
Slide 35: Investment Highlights
Investment Highlights Adaptable Therapeutic Filtration Device Platform Our Products Address Unmet Medical Needs Our Products Address Large Markets Early Adopter Distribution Channel in Place 4 Paths To Early Revenue New Clinical Programs
Slide 36: Presenter Information
Presenter Information Jim Joyee Chairman, CEO Aethion Medical, Inc (858) 459-7800 x301 jj@acthionmedical.com
Slide 37: 8010 University Center Lane, San Diego
8010 University Center Lane, Suite 660 San Diego, CA. 92122 way AsthlonMedical com
Aethlon Medical — LHA Life Sciences & Medical Technology Virtual Conference (June 2011) on 6ix